Normal view MARC view ISBD view

Cost-effectiveness of a human papillomavirus vaccine : [publication] : a comparative study between Switzerland, Romania and the Gambia /

by Kind, André B.
Material type: materialTypeLabelBookPublisher: 2009Description: 35 Bl. : Tabl. ; 30 cm.SAPHIR theme(s): Maladies - Pathologies | Santé sexuelle et reproductiveMeSH subject(s): Papillomavirus Vaccines | Cost-Benefit Analysis | Vaccination | Papillomavirus Infections | Uterine Cervical Neoplasms | Cross-Cultural Comparison | Vaccination -- economics | Papillomavirus Infections -- prevention & control | Uterine Cervical Neoplasms -- prevention & control | Switzerland | Romania | Gambia | Comparative StudyPUBLICATION TYPE SAPHIR: DissertationSummary: Background: Invasive cervical cancer (ICC) causes a tremendous individual, social and economical burden. Marked geographical variations in ICC occurrence are negatively correlated with prosperity. Switzerland (CH), Romania (RO) and The Gambia (TG) are examples of the broad spectrum of global socio-economic disparity. Since lately vaccines against the ICC oncogenic human papillomavirus genotypes HPV 16 and 18 are on the marked in CH and RO, and the introduction of subsidised vaccines in developing countries like TG is considered. We evaluated the clinical impact and cost-effectiveness of a HPV 16/18 vaccination in the three countries and compared the results. Design: Hypothetical cohorts of 100'000 women in each of the three countries were followed during their lifetime in a Markov model. We examined the current course of HPV infection and added vaccination in the second strategy. Results: Compared to the current situation, adding a HPV 16/18 vaccine reduced ICC incidence 78%, 92% respectively 61 % in CH, RO and TG during lifetime for costs of 18%, 22% respectively 56% of the per capita gross domestic product. Conclusions: Addition of a HPV 16/18 vaccine to the current practiced HPV course is very cost-effective in all three countries, but even with its introduction global health disparities will further increase. [Authors, p. 1]
No physical items for this record

Main text in English, Kritik auf Deutsch

Background: Invasive cervical cancer (ICC) causes a tremendous individual, social and economical burden. Marked geographical variations in ICC occurrence are negatively correlated with prosperity. Switzerland (CH), Romania (RO) and The Gambia (TG) are examples of the broad spectrum of global socio-economic disparity. Since lately vaccines against the ICC oncogenic human papillomavirus genotypes HPV 16 and 18 are on the marked in CH and RO, and the introduction of subsidised vaccines in developing countries like TG is considered. We evaluated the clinical impact and cost-effectiveness of a HPV 16/18 vaccination in the three countries and compared the results. Design: Hypothetical cohorts of 100'000 women in each of the three countries were followed during their lifetime in a Markov model. We examined the current course of HPV infection and added vaccination in the second strategy. Results: Compared to the current situation, adding a HPV 16/18 vaccine reduced ICC incidence 78%, 92% respectively 61 % in CH, RO and TG during lifetime for costs of 18%, 22% respectively 56% of the per capita gross domestic product. Conclusions: Addition of a HPV 16/18 vaccine to the current practiced HPV course is very cost-effective in all three countries, but even with its introduction global health disparities will further increase. [Authors, p. 1]